These 5 Hot Stocks Have Only ‘Buy’ Ratings From The Street

Which stocks are analysts the most bullish on? Stocks with no ‘hold’ or ‘sell’ ratings- and a pure “Strong Buy” analyst consensus to boot. Using TipRanks powerful stock screener, we set out to pinpoint 5 stocks that command the unanimous support of the Street.

You can customize the screener settings to match your investment strategy. In this case we selected filters for mega/ large cap stocks with a Strong Buy consensus from both analysts and from best-performing analysts. These are the top analysts with the highest success rate and average return.

From the results, you can immediately see a pie chart showing the spread of analyst ratings on that stock over the last three months. And if you hover your mouse over the pie chart, the exact number of ratings (buy, hold and sell) pop up:

This makes it easy to spot stocks with only buy ratings- and if you want you can click on the stock to reveal its share price trajectory over time. This is important if you want to assess the volatility and general price trends for the stock over different time periods, from 5 days all the way to 5 years.

So without further delay, here are five top stocks that you should follow now:

1. Align Tech

Dental device company Align Tech (NASDAQ:ALGN) is the name behind the invisible orthodontics market (for example, see the Invisalign transparent teeth straighteners). In the last three months, ALGN has received 8 buy ratings. These analysts have an average $180 price target which suggests 6.4% upside potential from current share price.

“We reiterate our Buy rating on ALGN and raise our target price to $180, from $138, after ALGN again reported a robust 2Q beat on strong growth across all channels and markets” comments four-star Roth Capital analyst Chris Lewis.

Lewis is optimistic on Align’s opportunities in the teenager market and says that: 

The sustained teen acceleration leaves us increasingly encouraged that teen may be in the early stages of enjoying a long-term inflection. We view ALGN as one of the premier growth stories in Med Tech and continue to recommend the name as a core long-term holding.”